Basal cell carcinoma - Carcinoma Cealla Basal
☆ AI Dermatology — Free Service
Ann an toraidhean 2022 Stiftung Warentest às a’ Ghearmailt, cha robh sàsachd luchd-cleachdaidh le ModelDerm ach beagan nas ìsle na le co-chomhairlean telemedicine pàighte.
Ann an toraidhean 2022 Stiftung Warentest às a’ Ghearmailt, cha robh sàsachd luchd-cleachdaidh le ModelDerm ach beagan nas ìsle na le co-chomhairlean telemedicine pàighte.
Thathas gu tric a’ faighinn a-mach gu bheil leòintean le ulcair a’ toirt buaidh air craiceann an t-sròin ann an daoine nas sine, mar Carcinoma Cealla Basal (Basal cell carcinoma). Tha an t-sròin na làrach choitianta airson an seòrsa seo de aillse craiceann.
Dh'fhaodadh Carcinoma Cealla Basal (Basal cell carcinoma) a nochdadh le crìochan neo‑riaghailteach agus ulcair.
Faodar mearachd a dhèanamh ann an aithneachadh Carcinoma Cealla Basal (Basal cell carcinoma) mar gob.
relevance score : -100.0%
ReferencesIs e Basal cell carcinoma (BCC) an seòrsa aillse craiceann as cumanta. Is e foillseachadh solais na grèine a’ phrìomh adhbhar. Cha mhòr a h-uile cùis BCC a’ nochdadh comharran gràineag cus‑ghnìomhach ann an anailis moileciuil. Tha diofar leigheasan rim faighinn agus air an taghadh a rèir cunnart ath‑chuairteachaidh, cudromachd gleidheadh, roghainn euslaintich, agus ìre galair.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinomas an seòrsa aillse craiceann as cumanta ann an inbhich le craiceann cothromach aois 50 agus nas sine. Tha na h-àireamhan aca ag èirigh air feadh an t-saoghail, gu h-àraidh mar thoradh air a bhith fosgailte do sholas na grèine. Faodaidh cuid de shuidheachaidhean ginteil cur ri buailteachd dhaoine a tha a’ leasachadh na cansean sin aig aois nas òige. Tha Basal cell carcinomas eadar-dhealaichte ann an doimhneachd, bho leòintean uachdarach gu nodular, agus tha iad furasta an làimhseachadh ach feumaidh cuid a dhaoine ann an sgiobaidhean meidigeach sònraichte deasbad. Tha an prognosis an urra ris a’ choltas gun till aillse no gun dèan e milleadh air maothran faisg air làimh. Is e lannsaireachd an làimhseachadh àbhaisteach airson a’ mhòr-chuid de chùisean, a’ dèanamh cinnteach gun tèid a thoirt air falbh gu mionaideach le cothroman ìosal gun till iad a-rithist. Faodaidh dòighean nach eil cho èifeachdach dèiligeadh ri lotan uachdar.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Is e lannsaireachd an prìomh làimhseachadh airson BCC. Airson BCC àrd‑chunnart no ath‑chuairteachaidh, gu sònraichte ann an raointean èiginneach, tha moladh air lannsaireachd fo smachd micrografach. Faodaidh euslaintich le BCC le cunnart ìosal beachdachadh air làimhseachadh gnàthach no dòighean millteach. Tha leigheas photodynamic ag obair gu math airson BCC nodular uachdarach le cunnart ìosal. Airson BCC adhartach gu h‑ionadail no meatastatach, tha moladh air luchd‑dìon gràineag (vismodegib, sonidegib). Ma tha adhartas galair ann no neo‑fulangas ri luchd‑bacadh gràineag, faodar beachdachadh air immunotherapy le anti‑PD1 antibody (cemiplimab). Tha radiotherapy na dheagh roghainn dha euslaintich nach urrainn lannsa fhaighinn, gu sònraichte aosran nas sine. Faodar beachdachadh air electrochemotherapy mura h‑eil lannsaireachd no radiotherapy na roghainn.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Tha factaran cunnairt a’ toirt a-steach a bhith fosgailte do sholas ultraviolet, leigheas rèididheachd, eòlas fad-ùine air arsenic agus droch ghnìomhachd siostam dìon (me tar-chuir organan). Tha a bhith fosgailte do sholas UV rè leanabachd gu sònraichte cronail.
Às deidh breithneachadh le biopsy, mar as trice bidh làimhseachadh le toirt air falbh lannsaireachd. Faodaidh seo a bhith air a ghearradh gu sìmplidh ma tha an aillse beag; mura h-eil an aillse beag, mar as trice thathar a’ moladh lannsaireachd Mohs.
Tha carcinoma cealla basal a’ dèanamh suas co-dhiù 32 % de gach aillse air feadh na cruinne. A-mach à cansearan craiceann a bharrachd air melanoma, tha timcheall air 80 % nan cansearan cealla basal. Anns na Stàitean Aonaichte, tha carcinoma cealla basal a’ toirt buaidh air timcheall air 35 % de fhireannaich gheala agus 25 % de bhoireannaich gheal aig àm air a’ bheatha.
○ Diagnosis agus Làimhseachadh
#Dermoscopy
#Skin biopsy
#Mohs surgery